NN6 NanoRepro AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company offers products in the areas of family planning, preventive healthcare, intolerances, and infectious diseases. It also develops and commercializes immunochromatographic lateral flow tests; and point of care testing for hospitals and medical practices. NanoRepro AG was incorporated in 2007 and is headquartered in Marburg, Germany.…
Industry Peers
Diagnostics & ResearchKey Statistics
About NanoRepro (ETR: NN6)
›
NanoRepro (ETR: NN6) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 20 employees.
The shares were at 1.405 EUR on 20 November 2026, down 9.4% over 52 weeks. Its 52-week range is 1.310 EUR to 2.400 EUR: the price is 41.5% below the high and 7.3% above the low.
Its market capitalisation is 17.72M EUR.
NanoRepro reports return on equity of -5.4%, an operating margin of -45.7% and revenue down 11.3% year over year.
It holds more cash than debt, a net cash position of 6.55M EUR. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 4.475 EUR is 218.5% above the current price.